Free tool
FAERS Monitor: Rukobia
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212950 or its brand name (Rukobia, Fostemsavir Tromethamine). Reports on generic versions are filed under their own applications.
Reports
243
Serious
77
32% of reports
Hospitalization
24
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use30
- nausea17
- death16
- product dose omission issue15
- drug ineffective14
- viral load increased12
- rash11
- dizziness10
- fatigue10
- pathogen resistance10
- product residue present9
- virologic failure9
- wrong technique in product usage process9
- diarrhoea8
- anxiety7
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 10 |
| 2021 | 28 |
| 2022 | 46 |
| 2023 | 52 |
| 2024 | 38 |
| 2025 | 46 |
| 2026 | 23 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,916 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| viral load increasedSignal | 12 | 268.4 | 154.4 | 2,926 |
| virologic failureSignal | 9 | 145.1 | 76.4 | 1,146 |
| product residue presentSignal | 9 | 144.7 | 76.2 | 1,143 |
| pathogen resistanceSignal | 10 | 95.1 | 51.8 | 839 |
| product dose omission issueSignal | 15 | 4.4 | 2.7 | 37 |
| wrong technique in product usage processSignal | 9 | 3.8 | 2.0 | 16 |
| off label useSignal | 30 | 3.0 | 2.1 | 39 |
| rashSignal | 11 | 2.2 | 1.2 | 6 |
| anxiety | 7 | 2.1 | 1.0 | 3 |
| nausea | 17 | 1.9 | 1.2 | 6 |
| dizziness | 10 | 1.7 | 0.9 | 2 |
| death | 16 | 1.6 | 1.0 | 3 |
| fatigue | 10 | 1.1 | 0.6 | 0 |
| diarrhoea | 8 | 1.1 | 0.5 | 0 |
| drug ineffective | 14 | 0.9 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.